Comparing VENEZE Peptide Hair Serum and 2% Minoxidil for Treating Androgenetic Alopecia in Adults Randomized Double-Blind Study on Hair Growth and Safety

What this Trial Is About

Researchers are evaluating the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in adults with androgenetic alopecia pattern hair loss. This condition affects both men and women and can impact quality of life. The study aims to measure improvement in hair growth, including changes in hair density and thickness, while also assessing safety and patient-reported outcomes. Participants will be randomly assigned in a double-blind manner to apply either the VENEZE peptide factor hair serum or a 2% minoxidil solution topically to the scalp twice daily for 24 weeks. Both treatments are administered according to the study protocol. The study includes two groups one using the peptide serum and the other using minoxidil as an active comparator. During the study, participants will attend scheduled visits where researchers will measure hair density, hair thickness, and terminal hair count at 12 and 24 weeks. Additional assessments include the Investigator Global Aesthetic Improvement Scale, androgenetic alopecia severity, patient global assessments, and monitoring for any adverse events. Participants are expected to maintain consistent hair color and hairstyle and attend all visits throughout the 24-week treatment period.

VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia